Search - tctmd.com

Displaying 141 - 160 of 197

Sort: Relevancy | Date

Presentation TCT 2015

A Master Class in Atherectomy: Choices, Strategies, and Execution

Presenter: Prakash Krishnan, Mahmood K. Razavi

October 11, 2015

Presentation TCT 2015

Biomimetic Stents: Rationale and Current Clinical Results

Presenter: Prakash Krishnan, Mahmood K. Razavi, Eric J. Dippel

October 11, 2015

Presentation TCT 2015

Adventitial Injection Therapy for Restenosis: Rationale and Clinical Results to Date

Presenter: Prakash Krishnan, Mahmood K. Razavi, Christopher D. Owens

October 11, 2015

Presentation TCT 2015

Update on Bioresorbable Scaffolds for PAD

Presenter: Prakash Krishnan, Mahmood K. Razavi

October 11, 2015

Presentation TCT 2015

Evolving Endovascular Treatment Strategies for Femoral-Popliteal Disease in a DES and DCB World

Presenter: Gary M. Ansel, Michael R. Jaff

October 11, 2015

Presentation TCT 2015

Review and Perspectives of the Global Registry Data for Antiproliferative Therapies

Presenter: Gary M. Ansel, Michael R. Jaff, John R. Laird Jr

October 11, 2015

Presentation TCT 2015

Review of Multicenter, Randomized Outcomes Data of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA, and DEFINITIVE AR

Presenter: Gary M. Ansel, Michael R. Jaff, Ravish Sachar

October 11, 2015

Presentation TCT 2015

Peering Through the Veil: Outcomes Reporting in SFA Intervention Decoded

Presenter: Gary M. Ansel, Michael R. Jaff, William A. Gray

October 11, 2015

Presentation TCT 2015

Everything You Wanted to Know About Endovascular Radiation Hazards but Were Afraid to Ask

Presenter: Gary M. Ansel, Michael R. Jaff, Lindsay S. Machan

October 11, 2015

Presentation TCT 2015

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Presenter: Gary M. Ansel, Michael R. Jaff, Ori Ben-Yehuda

October 11, 2015

Presentation TCT 2015

Is Peripheral Vascular Intervention Cost-effective? If So, From Whose Perspective?

Presenter: Gary M. Ansel, Michael R. Jaff

October 11, 2015

Presentation TCT 2015

Debate: For SFA Disease I Prefer a Drug-Coated Balloon With Provisional Bare-Metal Stenting

Presenter: Julie Logan, George L Adams

October 11, 2015

Presentation TCT 2015

Debate: For SFA Disease I Prefer a Drug-Eluting Stent!

Presenter: Julie Logan, William A. Gray

October 11, 2015

Presentation CCVVC 2015

My Algorithm for Treatment of Calcified SFA Lesions: Available Data, Role of DCB - DES, Atherectomy & Supera

Presenter: Fabrizio Fanelli

June 18, 2015

Presentation CCVVC 2015

Endovascular Management of SFA Instent Restenosis: Role of Atherectomy Drug-Eluting Stents

Presenter: Craig M. Walker

June 18, 2015

Presentation CCVVC 2015

Drug Eluting Stents in the treatment of SFA disease: Data and Current Trends

Presenter: Suhail Dohad

June 18, 2015

Presentation CCVVC 2015

Drug Coated Balloon in the Management of SFA Disease: Data & Current Trends

Presenter: Fabrizio Fanelli

June 18, 2015

Presentation ISET 2015

Recanalization of SFA Popliteal Arteries: Flossing and Other Solutions

Presenter: Alan H. Matsumoto

February 02, 2015

Presentation ISET 2015

New Insights from the IN.PACT SFA Randomized Trial

Presenter: Gunnar Tepe

February 02, 2015

Presentation ISET 2015

Benefits of DCB in SFA Disease

Presenter: Thomas Zeller

February 01, 2015

Advertisement

A Master Class in Atherectomy: Choices, Strategies, and Execution

Biomimetic Stents: Rationale and Current Clinical Results

Adventitial Injection Therapy for Restenosis: Rationale and Clinical Results to Date

Update on Bioresorbable Scaffolds for PAD

Evolving Endovascular Treatment Strategies for Femoral-Popliteal Disease in a DES and DCB World

Review and Perspectives of the Global Registry Data for Antiproliferative Therapies

Review of Multicenter, Randomized Outcomes Data of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA, and DEFINITIVE AR

Peering Through the Veil: Outcomes Reporting in SFA Intervention Decoded

Everything You Wanted to Know About Endovascular Radiation Hazards but Were Afraid to Ask

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Is Peripheral Vascular Intervention Cost-effective? If So, From Whose Perspective?

Debate: For SFA Disease I Prefer a Drug-Coated Balloon With Provisional Bare-Metal Stenting

Debate: For SFA Disease I Prefer a Drug-Eluting Stent!

My Algorithm for Treatment of Calcified SFA Lesions: Available Data, Role of DCB - DES, Atherectomy & Supera

Endovascular Management of SFA Instent Restenosis: Role of Atherectomy Drug-Eluting Stents

Drug Eluting Stents in the treatment of SFA disease: Data and Current Trends

Drug Coated Balloon in the Management of SFA Disease: Data & Current Trends

Recanalization of SFA Popliteal Arteries: Flossing and Other Solutions

New Insights from the IN.PACT SFA Randomized Trial

Benefits of DCB in SFA Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content